ClinicalTrials.gg
CompletedNCT01356498Updated Dec 2, 2011Results posted

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

A Phase 3 interventional study of pegloticase in Gout, sponsored by Savient Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-02.

Sponsored by Savient Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
6th of 14
151 · median 93
Started
2006
with 1 other
Phase 3
4 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
4 of 14
Savient Pharmaceuticals

Among the 14 studies testing pegloticase in Gout, this one is the 6th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 3, and was the 5th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • gout
  • chronic gout
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed treatment in one of two double-blind, placebo controlled studies of PEG-uricase in subjects with hyperuricemia and symptomatic gout

Exclusion criteria

Exclusion Criteria:

  • unstable angina
  • uncontrolled arrhythmia
  • uncontrolled hypertension
  • end stage renal disease requiring dialysis
  • anemia
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    q2 RCT

    Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study

    Biological: pegloticase

  • Experimental
    q4 RCT

    Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study

    Biological: pegloticase

  • Experimental
    Placebo in RCT

    Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE

    Biological: pegloticase

Interventions

06

What researchers measure

Primary outcomes

  1. Uric Acid (mg/dL)

    Uric acid measured at 3 month-intervals

    Time frame: Week 13, Week 25, Week 53, Week 101

Secondary outcomes

  1. Tophus Response

    Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus.

    Time frame: Up to 2 years

  2. Patient Reported Outcome: SF-36 Physical Component Summary Score

    SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best). The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status.

    Time frame: RCT Week 25; OLE Week 25; OLE Week 53, OLE Week 77, OLE Week 101

  3. Gout Flare Frequency

    The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment

    Time frame: Up to 2 years

  4. Gout Flare Incidence

    Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval.

    Time frame: Assessed in 3-month intervals up to 2 years

07

Results

Posted Dec 2, 2011

Participant flow

Subjects completing one of the randomized, controlled Phase 3 clinical trials (RCTs) of pegloticase \[C0405 and C0406 (NCT00325195)\] were invited to participate in this open-label extension study.

Participant flow — Overall Study
Milestoneq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
Started352523222816
Completed241711882
Not completed11812142014

Outcome measures

PrimaryUric Acid (mg/dL)

Uric acid measured at 3 month-intervals

Time frame:
Week 13, Week 25, Week 53, Week 101
Reported as:
Mean · mg/dL
Uric Acid (mg/dL)
mg/dLq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
OLE Week 131.33 ± 3.1031.91 ± 4.0825.06 ± 4.5389.76 ± 1.3469.66 ± 2.5298.08 ± 3.561
OLE Week 251.4 ± 3.1961.95 ± 3.7614.69 ± 4.4548.89 ± 3.9849.94 ± 2.6468.09 ± 3.536
OLE Week 530.87 ± 2.3271.55 ± 3.6902.7 ± 4.2559.18 ± 2.9469.59 ± 2.7826.45 ± 3.248
OLE Week 1010.84 ± 2.6191.47 ± 3.3174.29 ± 3.9857.7 ± 4.2449.42 ± 1.9618.5 ± NA
SecondaryTophus Response

Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus.

Time frame:
Up to 2 years
Reported as:
Number · participants
Tophus Response
participantsq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
Complete Response191310473
Partial Response403421
SecondaryPatient Reported Outcome: SF-36 Physical Component Summary Score

SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best). The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status.

Time frame:
RCT Week 25; OLE Week 25; OLE Week 53, OLE Week 77, OLE Week 101
Reported as:
Mean · units on a scale
Patient Reported Outcome: SF-36 Physical Component Summary Score
units on a scaleq2 RCT, Responderq4 RCT ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT, Non-responderPlacebo in RCT, q4 in OLE
Baseline value (pre-pegloticase)34.92 ± 10.98834.11 ± 10.02227.55 ± 11.40533.71 ± 11.58132.8 ± 10.12936.2 ± 11.926
Final Visit value (LOCF)40.40 ± 13.39340.82 ± 7.48230.34 ± 11.13237.68 ± 10.29834.76 ± 11.41338.8 ± 13.155
SecondaryGout Flare Frequency

The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment

Time frame:
Up to 2 years
Reported as:
Mean · Flares
Gout Flare Frequency
Flaresq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
Months 1-30.4 ± 0.690.8 ± 0.902.3 ± 2.910.6 ± 0.901.3 ± 1.491.5 ± 1.41
Months 4-60.4 ± 0.960.7 ± 0.951.3 ± 2.171.0 ± 1.730.8 ± 0.940.8 ± 1.18
Months 7-90.0 ± 0.170.3 ± 0.541.2 ± 1.800.6 ± 1.200.6 ± 0.970.4 ± 1.01
Months 10-120.1 ± 0.300.2 ± 0.510.6 ± 1.180.9 ± 1.340.9 ± 1.460.4 ± 0.63
Months 16-180.1 ± 0.25.3 ± 0.440.2 ± 0.400.7 ± 1.180.6 ± 0.850.4 ± 0.89
Months 22-240.1 ± 0.370.1 ± 0.230.4 ± 0.670.3 ± 0.650.6 ± 0.530.7 ± 1.15
SecondaryGout Flare Incidence

Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval.

Time frame:
Assessed in 3-month intervals up to 2 years
Reported as:
Number · Percentage of participants
Gout Flare Incidence
Percentage of participantsq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
Months 1-325.756.065.245.567.968.8
Months 4-623.540.045.035.050.038.5
Months 7-93.024.043.827.842.922.2
Months 10-129.416.728.647.145.028.6
Months 16-186.525.018.233.338.920.0
Months 22-243.45.327.325.055.633.3

Adverse events

Collected over Up to 30 days post-treatment (maximum of 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
q2 RCT, Responder—9/35 (25.7%)34/35 (97.1%)
q4 RCT, Responder—7/25 (28%)25/25 (100%)
Placebo in RCT, q2 in OLE—8/23 (34.8%)23/23 (100%)
q2 RCT, Non-responder—7/22 (31.8%)21/22 (95.5%)
q4 RCT Non-responder—12/28 (42.9%)28/28 (100%)
Placebo in RCT, q4 in OLE—8/16 (50%)15/16 (93.8%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
Eventq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
Infusion related reactionGeneral disorders1/350/254/231/223/283/16
DiarrhoeaGastrointestinal disorders0/351/252/230/220/280/16
Deep Vein ThrombosisVascular disorders0/350/252/230/221/280/16
Chest painGeneral disorders0/351/250/230/222/280/16
AppendicitisInfections and infestations0/350/250/230/220/281/16
FasciitisMusculoskeletal and connective tissue disorders0/350/250/230/220/281/16
MyositisMusculoskeletal and connective tissue disorders0/350/250/230/220/281/16
Renal Failure AcuteRenal and urinary disorders1/350/250/231/221/281/16
Lumbar RadiculopathyNervous system disorders0/350/250/230/220/281/16
GlaucomaEye disorders0/350/250/230/220/281/16
Most frequent other events
Showing 10 of 43
Most frequent other events
Eventq2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLE
GoutMusculoskeletal and connective tissue disorders15/3519/2519/2316/2224/2813/16
Infusion Related ReactionGeneral disorders7/356/2513/238/2219/2812/16
Back PainMusculoskeletal and connective tissue disorders5/354/259/233/223/281/16
Pain in ExtremityMusculoskeletal and connective tissue disorders5/358/254/231/226/282/16
Upper Respiratory Tract InvectionInfections and infestations8/358/254/233/224/280/16
ArthralgiaMusculoskeletal and connective tissue disorders7/357/256/231/228/280/16
Oedema PeripheralGeneral disorders7/356/255/231/222/280/16
DiarrhoeaGastrointestinal disorders7/356/253/232/224/280/16
CoughRespiratory, thoracic and mediastinal disorders8/352/253/230/220/281/16
SinusititsInfections and infestations4/352/251/235/223/280/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)q2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLETotal
<=18 years0000000
Between 18 and 65 years201718162311105
>=65 years158565544
Age Continuous
Age Continuous(years)q2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLETotal
Mean62.4 ± 13.6658.6 ± 13.5956.6 ± 10.5352.0 ± 13.1253.5 ± 12.2554.6 ± 13.6256.8 ± 13.19
Sex: Female, Male
Sex: Female, Male(Participants)q2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLETotal
Female107444332
Male251819182413117
Region of Enrollment
Region of Enrollment(participants)q2 RCT, Responderq4 RCT, ResponderPlacebo in RCT, q2 in OLEq2 RCT, Non-responderq4 RCT Non-responderPlacebo in RCT, q4 in OLETotal
United States322222172713133
Canada0110002
Mexico32051314
08

Study locations

22 sites
  • Kaiser Permanente Medical Center, Clinical Trials Unit
    San Francisco, California 94118, United States
  • Pacific Arthritis Center Medical Group
    Santa Maria, California 93454, United States
  • Agilence Arthritis & Osteoporosis Medical Center
    Whittier, California 90606, United States
  • Veterans Affairs Medical Center
    Washington, District of Columbia 20422, United States
  • Arthritis & Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Ocala Rheumatology Research Center
    Ocala, Florida 34474, United States
  • St. Petersburg Arthritis Center
    St. Petersburg, Florida 33703, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Peter A. Holt, M.D.
    Baltimore, Maryland 21239, United States
  • Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Justus J. Fiechtner, MD, PC
    Lansing, Michigan 48910, United States
  • CentraCare Clinic
    St. Cloud, Minnesota 56377, United States
  • Rheumatology Associates of North Jersey
    Teaneck, New Jersey 07666, United States
  • Duke University Medical Center
    Durham, North Carolina 27302, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • STAT Research, Inc.
    Dayton, Ohio 45402, United States
  • David R. Mandel, MD, Inc.
    Mayfield Village, Ohio 44143, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Mid Atlantic Research Assoc.
    Philadelphia, Pennsylvania 19154, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Pillinger MH, Fields TR, Yeo AE, Lipsky PE. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase. J Rheumatol. 2020 Apr;47(4):605-612. doi: 10.3899/jrheum.190161. Epub 2019 Jun 15. PubMed 31203212 ↗
  • Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 4;16(2):R60. doi: 10.1186/ar4497. PubMed 24588936 ↗
  • Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318. PubMed 24286509 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2008
First posted
May 19, 2011
Start
Dec 2006
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Dec 2, 2011
Last update
Dec 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01356498
Lead sponsor
Savient Pharmaceuticals
Responsible party
Sponsor
First posted
May 19, 2011
Start date
Dec 2006
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Dec 2, 2011
Last update
Dec 2, 2011

Study contacts

Medical Director, M.D.
study director · Savient Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegloticase

Start the discussion